Ernexa Therapeutics Inc. Liabilities, Fair Value Adjustment
Ernexa Therapeutics Inc. (ERNA) reported Liabilities, Fair Value Adjustment of $100.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:LiabilitiesFairValueAdjustment · last filed 2025-11-07
- Ernexa Therapeutics Inc. liabilities, fair value adjustment for the quarter ending 2024-09-30 was $100.00K.
- Ernexa Therapeutics Inc. liabilities, fair value adjustment for the quarter ending 2024-06-30 was $100.00K.
- Ernexa Therapeutics Inc. liabilities, fair value adjustment for the quarter ending 2023-03-31 was $45.00K, a 93.80% decline year-over-year.
- Ernexa Therapeutics Inc. liabilities, fair value adjustment for the quarter ending 2022-12-31 was -$302.00K.
- Ernexa Therapeutics Inc. liabilities, fair value adjustment for fiscal 2022 was -$11.39M.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2024-09-30 | $100.00K 10-Q · filed 2025-11-07 | $200.00K derived: sum of 2 quarters · filed 2025-11-07 | $100.00K 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-13 | $100.00K 10-Q · filed 2025-08-13 | ||
| 2023-03-31 | $45.00K 10-Q · filed 2023-05-11 | -$257.00K derived: sum of 2 quarters · filed 2023-05-11 | -$1.28M derived: sum of 3 quarters · filed 2023-05-11 | -$12.07M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | -$302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$1.33M derived: sum of 2 quarters · filed 2023-03-20 | -$12.12M derived: sum of 3 quarters · filed 2023-03-20 | -$11.39M 10-K · filed 2023-03-20 |
| 2022-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$11.81M derived: sum of 2 quarters · filed 2022-11-14 | -$11.09M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$10.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$10.06M 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $726.00K 10-Q · filed 2022-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |